At Meril Genomics Laboratory, we introduce OncoGuide Pro, an advanced NGS-based test combining a 680-gene panel and Circulating Tumor Cell (CTC) quantification to predict cancer prognosis, identify actionable mutations, and guide personalized treatment strategies. Designed for solid tumors (e.g.. breast, lung, colorectal), this comprehensive assay empowers oncologists to tailor therapies based on genomic drivers and metastatic potential.
Liquid Biopsy – Pan Cancer
Precision Oncology Through Genomic & CTC Analysis
OncoGuide Pro: Key Features
600-Gene NGS Panel
Somatic Mutations:
INDels, Fusions, CNVs, and hotspots in oncogenes (EGFR, BRAF, KRAS), tumor suppressors (TP53, PTEN), and DNA repair genes (BRCA1/2, ATM)
Tumor Mutational Burden:
Predicts response to immunotherapy
Biomarkers for Targeted Therapy:
HER2, PD-L1, ROS-1, ALK, NTRK1, and checkpoint markers (e.g., PD-L1 amplification)
CTC Quantification & Phenotyping
Size-Based Enrichment:
Isolates CTCs from blood using microfludic filtration
Prognostic Value:
High CTC counts correlate with aggressive disease and metastasis
Protein Biomarkers:
EpCAM/CK, vimentin (EMT marker), atypical markers (e.g., melanocytes)
Treatment Guidance
Matches detected variants to FDA-approved targeted therapies (e.g., osimertinib for EGFR T790M).
Recommends immunotherapy eligibility based on TMB/MSI status.
Flags clinical trial opportunities for rare mutations.
Predicts chemotherapy resistance/sensitivity (e.g., TOP2A amplification).
Key Advantages
Dual-Modal Insight
Combines genomic and CTC data for holistic prognosis.
Comprehensive Coverage
680 genes span all major cancer pathways and therapy targets.
Rapid Turnaround
Results in 7-10 business days.
Actionable Reporting
Clear therapeutic recommendations for oncologists.
Limitations
Complementary Tool
Complementary Tool: Requires integration with imaging and clinical findings.
Tumor Heterogeneity
May miss subclonal variants below 1% allele frequency.
Why Choose Meril Genomics Laboratory?
Expert Clinical Team
Our laboratory is led by world-class geneticists and oncologists providing expert clinical insights and precise diagnostic interpretations.
Cutting-Edge Technology
AI-driven algorithms refine variant prioritization and ensure high precision in identifying actionable genomic mutations.
Global Standards
Adherence to international quality, compliance, and innovation standards ensures reliable and globally recognized results.
Collaborative Care
A multidisciplinary approach ensuring the best outcomes for patients through seamless research and clinical excellence.
Clinical Validations
01
Who Should Use OncoGuide Pro?
Patients With
- Newly diagnosed advanced/metastatic cancer.
- Disease progression on current therapy.
- Rare or complex mutations requiring tailored treatment.
Oncologists Seeking
- Newly diagnosed advanced/metastatic cancer.
- Disease progression on current therapy.
- Monitoring of minimal residual disease (MRD).
02
Understanding Your Results
Genomic Findings
- Actionable Mutations: e.g., EGFR exon 19 deletion recommend osimertinib.
- Resistance Markers: e.g., ESR1 mutations in breast cancer avoid aromatase inhibitors.
- TMB-High/MSI-H: Eligible for checkpoint inhibitors (e.g., pembrolizumab).
03
CTC Results
Low Count (<5 CTCs/7.5 mL):
- Favorable prognosis.
High Count (≥5 CTCs/7.5 mL):
- High metastasis risk; consider aggressive therapy.
04
Prognostic Risk Score
Low Risk:
- 5-year survival >70%; standard therapy advised.
High Risk:
- 5-year survival <30%; recommend clinical trials or combination regimens.
Have any questions?
We are here to answer